{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperhidrosis/management/management/","result":{"pageContext":{"chapter":{"id":"e0426c02-494d-544f-ac4b-5a344571652a","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 7f8c376c-5cfc-45e8-afc1-d15a17a64f11 --><h2>Scenario: Management</h2><!-- end field 7f8c376c-5cfc-45e8-afc1-d15a17a64f11 -->","summary":"Covers the management of people with primary focal hyperhidrosis in primary care.","htmlStringContent":"<!-- begin item e31f4a17-d919-4bc3-9f63-2cd3d76fbe89 --><!-- begin field 4dff1822-6dfa-4680-91d0-acbc0156f63e --><p>From age 12 years onwards.</p><!-- end field 4dff1822-6dfa-4680-91d0-acbc0156f63e --><!-- end item e31f4a17-d919-4bc3-9f63-2cd3d76fbe89 -->","topic":{"id":"d2b54f08-d9cb-5147-a5aa-27e00b5cfd82","topicId":"9dacba69-b1b5-408f-a26d-a8e884033a25","topicName":"Hyperhidrosis","slug":"hyperhidrosis","lastRevised":"Last revised in May 2018","chapters":[{"id":"51b68ff2-e22f-5146-98b1-ed247449fada","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d247fa3c-c9d7-571f-9348-9d3a5b9a827f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3db15061-64ce-5067-8778-049202743014","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5d7852f4-9b06-5320-86de-ee56104314fc","slug":"changes","fullItemName":"Changes"},{"id":"37a4f575-9e64-5591-9459-613a50da6a5b","slug":"update","fullItemName":"Update"}]},{"id":"6608a015-2abe-5be8-882a-844689719b29","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2b31616d-6688-52e8-abfe-1c1e9567773c","slug":"goals","fullItemName":"Goals"},{"id":"164bcdd9-2d27-5afc-8857-f691d732e91a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f04b5274-abcd-5e07-9d0e-218d1b25b64a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"35e097f0-6a28-54ce-91f0-09584dff79fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0c245ac4-9908-5ec7-9443-c8d80afba273","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"479a66f8-4820-5838-babb-6b95327bf868","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e78f871f-1030-583b-b3a3-fd5932d63577","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f573ecee-b6e5-56a9-b610-ad80005d58b7","slug":"definition","fullItemName":"Definition"},{"id":"5105b210-71a6-505f-9fe7-96123ea1beba","slug":"causes","fullItemName":"Causes"},{"id":"3064f161-ea2d-5e49-9dbb-092faa5d5f71","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2e2ec09e-2d90-5f72-b368-813dea5aee6e","slug":"complications","fullItemName":"Complications"},{"id":"8132bf09-7bc9-55ce-8d34-d18405a2c171","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"13f16bec-4872-59e8-9996-2d88a053d081","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dfa50ec8-3fda-51b5-9903-61e58cc06753","slug":"assessment","fullItemName":"Assessment"}]},{"id":"45eb7b55-769c-50ef-9ce2-44c27469518c","fullItemName":"Management","slug":"management","subChapters":[{"id":"e0426c02-494d-544f-ac4b-5a344571652a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f83d14e6-24e3-513f-8d39-8b68803222b0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"00e65205-feb9-59d3-8035-446868d1caab","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b7466396-123d-5050-8dd8-88ec7ce286f7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0574994c-afef-578e-ab8a-e3d78c0757e3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"68b43c06-7da3-5e66-ae57-bc294e301587","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"67e38cee-224f-54bd-ad61-431d5cc9c006","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"373675d4-86fc-5734-962f-d2aad8d56169","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"26f4cbb7-dfc9-5c02-9786-950141a26758","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"45eb7b55-769c-50ef-9ce2-44c27469518c","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"06c5c0ce-09bf-5ae7-9ad3-3338a28dba2e","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field a218a33c-6372-444d-b477-b9f66703a6c3 --><h3>How should I manage a person with primary focal hyperhidrosis?</h3><!-- end field a218a33c-6372-444d-b477-b9f66703a6c3 -->","summary":null,"htmlStringContent":"<!-- begin item 92250744-47b9-46fa-95d1-b22d1c130318 --><!-- begin field 99ba2eb6-aef0-48b5-ba19-4dead9df9205 --><p><strong>If a person has a suspected diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperhidrosis/diagnosis/assessment/#diagnostic-criteria-for-primary-focal-hyperhidrosis\">primary focal hyperhidrosis</a>:</strong></p><ul><li><strong>Advise them to avoid any <a class=\"topic-reference internal-reference\" href=\"/topics/hyperhidrosis/diagnosis/assessment/\">identified triggers</a> where possible.</strong></li><li><strong>Advise on self-care management strategies:</strong><ul><li>For primary axillary hyperhidrosis:<ul><li>Use a commercial antiperspirant (as opposed to a deodorant) frequently.</li><li>Avoid tight clothing and manmade fabrics.</li><li>Wear white or black (as opposed to blue) clothing to minimize the signs of sweating.</li><li>Consider using underarm pads to absorb excess sweat and protect delicate or expensive clothing.</li></ul></li><li>For primary plantar hyperhidrosis:<ul><li>Wear moisture-wicking socks, changing them at least twice daily.</li><li>Use absorbent soles, and use absorbent foot powder twice daily.</li><li>Avoid occlusive footwear such as boots or sports shoes; wear leather shoes.</li><li>Alternate pairs of shoes on a daily basis to allow them to dry out fully before wearing them again.</li></ul></li></ul></li><li><strong>Provide information on sources of advice and support, such as:</strong><ul><li>The International Hyperhidrosis Society (website available at <a data-hyperlink-id=\"a91eeb8e-e279-4de8-8868-a8f7014fb02a\" href=\"https://www.sweathelp.org/\" target=\"_blank\">www.sweathelp.org</a>) which is an independent, non-profit organization providing information resources for people affected by hyperhidrosis and for healthcare professionals.</li><li>The British Association of Dermatologists' information leaflet <a data-hyperlink-id=\"47511c17-c694-4a12-b14c-a8f7014fb0cf\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=93&itemtype=document\" target=\"_blank\">Hyperhidrosis</a>.</li><li>The NHS information leaflet <a data-hyperlink-id=\"929fb6ab-29a8-4fb3-bc50-a8f7014fb0d3\" href=\"https://www.nhs.uk/conditions/excessive-sweating-hyperhidrosis/\" target=\"_blank\">Excessive sweating (hyperhidrosis)</a>.</li></ul></li><li><strong>Advise on the use of topical aluminium salt preparations for symptom relief.</strong><ul><li>Recommend the use of 20% aluminium chloride hexahydrate preparations such as roll-on antiperspirants and sprays, which are available over-the-counter.</li><li>Advise on the correct application technique:<ul><li>Apply at night just before sleep to skin of the axillae, feet, or hands which has been carefully dried (avoiding the eyes, mucous membranes, and broken skin).</li><li>Wash the product off in the morning.</li><li>Apply every 1–2 days as tolerated, until symptoms improve. Following this, use as required, which may be up to every 6 weeks.</li><li>Avoid shaving the area and using hair removal products within 12 hours of application, and do not bathe immediately before use.</li><li>For craniofacial hyperhidrosis, consider soaking lotion pads for application to the face (off-label use).</li></ul></li></ul></li><li><strong>If skin irritation occurs with the application of topical aluminium salt preparations:</strong><ul><li>Advise on the use of topical emollients and soap substitutes.</li><li>Advise the person to reduce the frequency of topical aluminium salt application until symptoms resolve.</li><li>Consider prescribing a mildly-potent topical corticosteroid in addition, such as hydrocortisone 1% cream to be applied once daily for up to two weeks.<ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information.</li></ul></li></ul></li><li><strong>Arrange to review the person six weeks after starting treatment,</strong> to assess the response to treatment.<ul><li>If there is a satisfactory response, treatment can be continued long-term.</li></ul></li><li><strong>If there is any underlying or associated anxiety,</strong> arrange appropriate management. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> for more information.<ul><li>Be aware that drug treatments such as selective serotonin reuptake inhibitors and propranolol may cause or worsen symptoms.</li></ul></li><li><strong>Arrange referral to a dermatologist to consider <a class=\"topic-reference internal-reference\" href=\"/topics/hyperhidrosis/management/management/#specialist-treatments\">specialist management</a>, if self-care measures and topical drug treatments are ineffective or not tolerated.</strong></li></ul><!-- end field 99ba2eb6-aef0-48b5-ba19-4dead9df9205 --><!-- end item 92250744-47b9-46fa-95d1-b22d1c130318 -->","subChapters":[{"id":"2c3e342c-0217-5b52-b241-41a227881484","slug":"specialist-treatments","fullItemName":"Specialist treatments","depth":4,"htmlHeader":"<!-- begin field 963c323e-d4fb-4831-a6e7-cac9cdcd0a92 --><h4>Specialist treatments</h4><!-- end field 963c323e-d4fb-4831-a6e7-cac9cdcd0a92 -->","summary":null,"htmlStringContent":"<!-- begin item 63d23284-afa6-4d18-8e72-48221a86b812 --><!-- begin field 326e9320-cded-478d-94a7-093f22ee728a --><p><strong>Access to specialist treatments for hyperhidrosis may require an individual funding request. Treatment options depend on symptom severity, body region affected, potential adverse effects and complications, local availability, and the person's wishes, and may include:</strong></p><ul><li>Oral and topical therapy<ul><li>Higher strength aluminium salts (up to 50%), and topical glutaraldehyde or formaldehyde may be used.</li><li>Topical glycopyrrolate (an antimuscarinic agent) may be useful for primary craniofacial hyperhidrosis (off-label indication).</li><li>Oral antimuscarinics, such as oxybutynin and glycopyrronium bromide decrease sweat secretion by competitive inhibition of acetylcholine at the muscarinic receptors near eccrine sweat glands (off-label indications).<ul><li>Their use may be limited by adverse effects such as dry mouth, blurred vision, constipation, or urinary retention.</li></ul></li></ul></li><li>Iontophoresis<ul><li>The sites of hyperhidrosis are immersed in warm water (or a wet contact pad may be applied) through which a weak electric current is passed. This introduces charged ions into the skin which inhibits the function of the sweat glands in that area.</li><li>It is mainly suitable for the palms and soles, as treatment of the axillae is less practical.</li><li>If unsuccessful, glycopyrronium bromide (an antimuscarinic agent) may be added to the water.</li><li>Maintenance treatment is typically required at intervals of 1–4 weeks, as recurrence of symptoms, is common after stopping treatment.</li><li>Adverse effects include transient discomfort, erythema, and vesicle formation at the treatment site.</li></ul></li><li>Botulinum A toxin<ul><li>Botulinum toxin is delivered by multiple intradermal injections to the affected areas.</li><li>It acts by inhibiting acetylcholine release from the sympathetic cholinergic nerve terminals that innervate sweat glands.</li><li>Botulinum toxin is licensed for the treatment of axillary hyperhidrosis and may also be used for palmar, plantar, and craniofacial hyperhidrosis (treatment is more painful in these areas). The effect may last for 6–9 months.</li><li>Adverse effects include pain during injections and compensatory sweating. Transient muscle weakness and loss of fine motor control have also been reported.</li></ul></li><li>Surgery<ul><li>Localized resection of eccrine sweat glands can be carried out using local anaesthesia and is useful for small areas of axillary hyperhidrosis.</li><li>Endoscopic thoracic sympathectomy (ETS) may be offered if other measures are ineffective or not tolerated.<ul><li>This involves division of the sympathetic chain over the neck of the ribs in the pleural cavity under general anaesthesia, usually by a vascular surgeon. It aims to prevent transmission of nerve signals from sympathetic ganglia to fibres innervating the areas producing excessive sweating.</li><li>It may be used for severe palmar, axillary, and sometimes craniofacial hyperhidrosis, and may provide permanent symptom relief.</li><li>Complications include compensatory hyperhidrosis elsewhere on the body such as the back or legs (very common), which typically starts 6–12 months after surgery. This may be a physiological response to a reduced surface area for body cooling, with activity being increased in areas left untreated.</li><li>Other complications include gustatory sweating (common), pneumothorax (common), atelectasis, and significant bleeding.<!--_c2a0_125_29_2c_                      --></li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Gelbard, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Mahendiran, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Walling and Swick, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hoorens and Ongenae, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Benson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Perera, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Stashak, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Wade, 2017</a>]</p><!-- end field 326e9320-cded-478d-94a7-093f22ee728a --><!-- end item 63d23284-afa6-4d18-8e72-48221a86b812 -->","subChapters":[]},{"id":"c3cd944e-e020-5b01-a65d-5d1e661deb4b","slug":"basis-for-recommendation-01d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7a0c3046-3e94-4154-9198-d6b176c49628 --><h4>Basis for recommendation</h4><!-- end field 7a0c3046-3e94-4154-9198-d6b176c49628 -->","summary":null,"htmlStringContent":"<!-- begin item 01d185fb-3d80-411e-973b-50300e31baa4 --><!-- begin field 50dd9d58-663a-4bc2-aa65-c236cb454cba --><p>The recommendations on the management of suspected primary focal hyperhidrosis are based on expert opinion in an international consensus statement <em>Recognition, diagnosis, and treatment of primary focal hyperhidrosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hornberger et al, 2004</a>], in a Canadian consensus statement <em>A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Solish et al, 2007</a>], and in review articles on hyperhidrosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Gelbard, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Mahendiran, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Walling and Swick, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hoorens and Ongenae, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Benson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Perera, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hamm, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Moraites, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Pariser, 2014</a>].</p><h5>Advice on self-management strategies</h5><ul><li>The recommendations on self-management are based on expert opinion in the international consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hornberger et al, 2004</a>] and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Benson, 2013</a>].</li></ul><h5>Advice on first-line use of topical aluminium salt preparations</h5><ul><li>The recommendations on the use of topical aluminium salt preparations are based on expert opinion in the international and Canadian consensus statements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hornberger et al, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Solish et al, 2007</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hoorens and Ongenae, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Walling and Swick, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Benson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Pariser, 2014</a>], and expert opinion in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">BNF 75, 2018</a>].<ul><li>Aluminium salt antiperspirants decrease the amount of sweat that is secreted by the eccrine sweat glands by causing mechanical obstruction of the distal gland ducts [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Perera, 2013</a>].</li><li>Preparations should be applied to dry skin at night to reduce the risk of skin irritation and burning, increase efficacy, and limit damage to clothing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Pariser, 2014</a>].</li></ul></li></ul><h5>Management of skin irritation</h5><ul><li>The recommendation to consider applying a mild-potency topical corticosteroid cream if there is skin irritation is based on expert opinion in the international consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hornberger et al, 2004</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Gelbard, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hoorens and Ongenae, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Perera, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Pariser, 2014</a>].</li></ul><h5>Management of associated anxiety</h5><ul><li>The recommendation to manage any underlying anxiety is extrapolated from expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Benson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hamm, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Moraites, 2014</a>] and is pragmatic, based on what CKS considers to be good medical practice. This is supported by the expert opinion of previous external reviewers of this CKS topic.</li><li>The information that various drug treatments including selective serotonin reuptake inhibitors and propranolol can cause or worsen sweating, is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Benson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Moraites, 2014</a>].</li></ul><h5>Arranging follow-up and referral</h5><ul><li>The recommendations on follow-up and referral if symptoms persist despite primary care management are based on expert opinion in a review article, which cites evidence that a maximal response from topical aluminium salt preparations is typically seen by six weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Benson, 2013</a>].</li><li>This is supported by expert opinion in the international consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Hornberger et al, 2004</a>] and in an additional review article, which state that dermatology referral should be arranged if adverse effects from topical aluminium salt preparations cannot be managed in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperhidrosis/references/\">Pariser, 2014</a>].</li></ul><!-- end field 50dd9d58-663a-4bc2-aa65-c236cb454cba --><!-- end item 01d185fb-3d80-411e-973b-50300e31baa4 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}